State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Institut de Génétique et Microbiologie, UMR, University Paris-Sud, 8621, Orsay, France.
Front Med. 2018 Feb;12(1):92-97. doi: 10.1007/s11684-017-0610-z. Epub 2017 Dec 29.
Investigations on the genetic diversity of Mycobacterium tuberculosis in China have shown that Beijing genotype strains play a dominant role. To study the association between the M. tuberculosis Beijing genotype and the drug-resistance phenotype, 1286 M. tuberculosis clinical isolates together with epidemiological and clinical information of patients were collected from the center for tuberculosis (TB) prevention and control or TB hospitals in Beijing municipality and nine provinces or autonomous regions in China. Drug resistance testing was conducted on all the isolates to the four first-line anti-TB drugs (isoniazid, rifampicin, streptomycin, and ethambutol). A total of 585 strains were found to be resistant to at least one of the four anti-TB drugs. The Beijing family strains consisted of 499 (53.20%) drug-sensitive strains and 439 (46.80%) drug-resistant strains, whereas the non-Beijing family strains comprised 202 (58.05%) drug-sensitive strains and 146 (41.95%) drug-resistant strains. No significant difference was observed in prevalence (χ= 2.41, P > 0.05) between the drug-resistant and drugsensitive strains among the Beijing family strains. Analysis of monoresistance, multidrug-resistant TB, and geographic distribution of drug resistance did not find any relationships between the M. tuberculosis Beijing genotype and drug-resistance phenotype in China. Results confirmed that the Beijing genotype, the predominant M. tuberculosis genotype in China, was not associated with drug resistance.
在中国，对结核分枝杆菌遗传多样性的研究表明，北京基因型菌株发挥着主导作用。为了研究结核分枝杆菌北京基因型与耐药表型之间的关系，从北京市结核病预防控制中心或结核病医院以及中国九个省或自治区收集了 1286 株结核分枝杆菌临床分离株，以及患者的流行病学和临床信息。对所有分离株进行了四种一线抗结核药物（异烟肼、利福平、链霉素和乙胺丁醇）的耐药性检测。共发现 585 株至少对一种抗结核药物耐药。北京家族菌株包括 499 株（53.20%）敏感株和 439 株（46.80%）耐药株，而非北京家族菌株包括 202 株（58.05%）敏感株和 146 株（41.95%）耐药株。北京家族菌株中，耐药株和敏感株的流行率（χ=2.41，P>0.05）差异无统计学意义。对单耐药、耐多药结核和耐药地理分布的分析也未发现中国结核分枝杆菌北京基因型与耐药表型之间存在任何关系。结果证实，北京基因型，即中国主要的结核分枝杆菌基因型，与耐药性无关。
